<!DOCTYPE html>
<html>
<head>
    <style>
        .annotation-head {
            padding-top: 7px;
        }

        .annotation-segment, .annotation-head {
            position: relative;
        }

        .anno {
            position: relative;
            text-align: center;
        }

        .label {
            -webkit-border-radius: 3px;
            -moz-border-radius: 3px;
            border-radius: 3px;

            display: inline-block;
            padding: 2px 0;
            font-size: 11.844px;
            font-weight: bold;
            line-height: 14px;
            color: #000000;
            text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.25);
            white-space: nowrap;
            vertical-align: baseline;
            background-color: #999999;
        }

        .marker {
            background: lightgreen;
        }

        .collapsible {
            background-color: #929af0;
            color: #444;
            cursor: pointer;
            padding: 18px;
            width: 100%;
            border: none;
            text-align: left;
            outline: none;
            font-size: 15px;
        }

        .collapsible:hover {
            background-color: #ccc;
        }

        .midcontainer {
            overflow: hidden;
            overflow-x: auto;
            white-space: nowrap;
            margin: 10px;
        }
        .abstractcontainer {
            margin: 10px;
            line-height: 200%;
        }

        .supercontainer {
            border-style: solid;
	        border-width: 1px;
	        border-color: black;
        	border-radius: 3px;
            margin: 10px;
        }
    </style>
    <script src="http://ajax.googleapis.com/ajax/libs/jquery/1.4.1/jquery.min.js" type="text/javascript"></script>
    <script src="http://ajax.googleapis.com/ajax/libs/prototype/1.6.1.0/prototype.js" type="text/javascript"></script>
    <script src="http://ajax.googleapis.com/ajax/libs/scriptaculous/1.8.3/scriptaculous.js"
            type="text/javascript"></script>
    <script type="text/javascript">
        (function ($) {
            String.prototype.width = function (font) {

                var f = font || '12px arial',
                    o = $('<div>' + this + '</div>')
                        .css({
                            'position': 'absolute',
                            'float': 'left',
                            'white-space': 'nowrap',
                            'visibility': 'hidden',
                            'font': f
                        })
                        .appendTo($('body')),
                    w = o.width();

                o.remove();

                return w;
            }

            $(document).ready(function () {
                $('.container').each(function () {
                    var c = $(this);
                    $(c).find('.marker').each(function () {
                        var $t = $(this),
                            pos = $t.attr('data-anno-label'),
                            id = $t.attr('head-id'),
                            annoStr = pos;
                        var total_width = 0;
                        $(c).find('.annotation-head .anno').each(function () {
                            total_width += $(this).width();
                        })
                        // create an annotation for each marker
                        var top = this.offsetTop - 5,
                            left = this.offsetLeft - total_width,
                            width = $t.width(),
                            style = 'style="top:' + top + 'px; left:' + left + 'px;width:' + width + 'px;"';

                        $(c).find('.annotation-head').append('<span class="anno label" ' + style + '>' + annoStr + '</span>');
                    });
                })
            });
        })(jQuery);

    </script>
</head>

<body>


<button type="button" class="collapsible">yosi - yakir</button>
        <div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi_:</b>  The other received chemotherapy including  <span class="marker" data-anno-id="0" data-anno-label="P1">prednisone</span>  ,  <span class="marker" data-anno-id="1" data-anno-label="P1">vincristine</span>  ,  <span class="marker" data-anno-id="2" data-anno-label="P1">cytarabine</span>  and  <span class="marker" data-anno-id="3" data-anno-label="P1">L-asparaginase</span>  , combined with intrathecal injections of methotrexate , dexamethasone and Ara-C and supporting treatment . </div></div><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yakir:</b>  The other received chemotherapy including  <span class="marker" data-anno-id="0" data-anno-label="P1">prednisone</span>  ,  <span class="marker" data-anno-id="1" data-anno-label="P1">vincristine</span>  ,  <span class="marker" data-anno-id="2" data-anno-label="P1">cytarabine</span>  and  <span class="marker" data-anno-id="3" data-anno-label="P1">L-asparaginase</span>  , combined with intrathecal injections of  <span class="marker" data-anno-id="4" data-anno-label="P1">methotrexate</span>  ,  <span class="marker" data-anno-id="5" data-anno-label="P1">dexamethasone</span>  and  <span class="marker" data-anno-id="6" data-anno-label="P1">Ara-C</span>  and supporting treatment . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>[Renal tubular acidosis as an initial manifestation in children with malignant lymphoma].</u></h4>Primary renal lymphoma is one of the malignant lymphomas that initially presents in the extra lymphonode, which is rarely seen in children. This study reported two cases of primary renal lymphoma in children who were definitively diagnosed by renal biopsy. Renal tubular acidosis was the initial manifestation in both cases. They were referred to the hospital with chief complaints of polydipsia, polyuria, debilitation, vomiting and anemia. Imaging and laboratory examinations showed bilateral renomegaly, hypocalcemia, hypophosphatemia, and metabolic acidosis. One of the patients discontinued therapy. <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>other</i></b> <b style='color:DodgerBlue;'><i>received</i></b> <b style='color:DodgerBlue;'><i>chemotherapy</i></b> <b style='color:DodgerBlue;'><i>including</i></b> <b style='color:MediumOrchid;'><i>prednisone</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>vincristine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>cytarabine</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>L-asparaginase</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>combined</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>intrathecal</i></b> <b style='color:DodgerBlue;'><i>injections</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>methotrexate</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>dexamethasone</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>Ara-C</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>supporting</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Twenty-three days after treatment, polydipsia and polyuria were relieved, and acidosis, kaliopenia and anemia were improved in the patient. There were no abnormal findings in the renal B-ultrasound re-examination. It was concluded that when a patient is suspected of renal lymphoma, diagnostic puncture and renal biopsy should be performed early. Early combined therapeutics including chemotherapy, radiation therapy, surgery and supporting treatments may result in a favorable prognosis in patients with this disease.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi_:</b>  Then , neoadjuvant chemotherapy ( NAC ) consisting of a combination of  <span class="marker" data-anno-id="0" data-anno-label="P1">5-fluorouracil</span>  ( 5-FU ) ,  <span class="marker" data-anno-id="1" data-anno-label="P1">oxaliplatin</span>  ,  <span class="marker" data-anno-id="2" data-anno-label="P1">irinotecan</span>  , and  <span class="marker" data-anno-id="3" data-anno-label="P1">leucovorin</span>  ( FOLFOXIRI ) was planned , followed by primary tumor resection . </div></div><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yakir:</b>  Then , neoadjuvant chemotherapy ( NAC ) consisting of a combination of  <span class="marker" data-anno-id="0" data-anno-label="C2">5-fluorouracil</span>  ( 5-FU ) ,  <span class="marker" data-anno-id="1" data-anno-label="C2">oxaliplatin</span>  ,  <span class="marker" data-anno-id="2" data-anno-label="C2">irinotecan</span>  , and  <span class="marker" data-anno-id="3" data-anno-label="C2">leucovorin</span>  ( FOLFOXIRI ) was planned , followed by primary tumor resection . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>A pathological complete response after neoadjuvant triplet chemotherapy for locally advanced transverse colon cancer.</u></h4>Perioperative chemotherapy could improve oncological outcomes for patients with advanced colon cancer. However, the effectiveness of triplet chemotherapy in the neoadjuvant setting is still unknown. ### Presentation Of Case A 61-year-old man was referred to our hospital due to abdominal distention. Abdominal computed tomography showed a huge, 18-cm mass in the right upper abdomen. Biopsy showed well-differentiated adenocarcinoma. Locally advanced transverse colon cancer T4b N2a M0 Stage IIIC was diagnosed. Considering the extensive invasion to surrounding organs and difficulties in achieving margin-negative surgery, an emergency ileostomy was performed first. <b style='color:DodgerBlue;'><i>Then</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>neoadjuvant</i></b> <b style='color:DodgerBlue;'><i>chemotherapy</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>NAC</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>consisting</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>5-fluorouracil</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>5-FU</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>oxaliplatin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>irinotecan</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>leucovorin</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>FOLFOXIRI</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>planned</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>followed</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>primary</i></b> <b style='color:DodgerBlue;'><i>tumor</i></b> <b style='color:DodgerBlue;'><i>resection</i></b> <b style='color:DodgerBlue;'><i>.</i></b> After 6 courses of treatment, the primary tumor shrank remarkably. Finally, laparoscopic radical extended right hemi-colectomy was performed. There were no residual tumor cells in resected specimens, including the primary tumor and surrounding lymph nodes. The pathological diagnosis was complete response. ### conclusion A case of pathological complete response after neoadjuvant treatment followed by radical resection was reported. Further research is needed to confirm the appropriate indications for neoadjuvant FOLFOXIRI therapy for patients with LACC.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi_:</b>  Twenty-seven received  <span class="marker" data-anno-id="0" data-anno-label="C1">rituximab</span>  mainly in addition to high-dose  <span class="marker" data-anno-id="1" data-anno-label="C1">cytarabine</span>  and  <span class="marker" data-anno-id="2" data-anno-label="C1">etoposide</span>  ( n = 18 ) and/or  <span class="marker" data-anno-id="3" data-anno-label="C1">ifosfamide</span>  ,  <span class="marker" data-anno-id="4" data-anno-label="C1">carboplatin</span>  , and  <span class="marker" data-anno-id="5" data-anno-label="C1">etoposide</span>  ( n = 7 ) . </div></div><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yakir:</b>  Twenty-seven received  <span class="marker" data-anno-id="0" data-anno-label="C3/C1/C2">rituximab</span>  mainly in addition to high-dose  <span class="marker" data-anno-id="1" data-anno-label="C1/C2">cytarabine</span>  and  <span class="marker" data-anno-id="2" data-anno-label="C1/C2">etoposide</span>  ( n = 18 ) and/or  <span class="marker" data-anno-id="3" data-anno-label="C3/C1">ifosfamide</span>  ,  <span class="marker" data-anno-id="4" data-anno-label="C3/C1">carboplatin</span>  , and  <span class="marker" data-anno-id="5" data-anno-label="C3">etoposide</span>  ( n = 7 ) . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Outcome of relapse in children and adolescents with B-cell non-Hodgkin lymphoma and mature acute leukemia: A report from the French LMB study.</u></h4>In order to describe relapsed B-cell non-Hodgkin lymphoma and mature acute leukemia in children/adolescents treated with the Lymphomes Malins B (LMB) regimen and their outcome in the <b style='color:Tomato;'><i>rituximab</i></b> era, relapses in the French LMB2001 study were reviewed. ### methods Between February 2001 and December 2011, 33 patients out of 773 (4.3%) relapsed; 27 had Burkitt lymphoma and six large B-cell histology. Median age at diagnosis was 10.1 years. One patient was initially treated in risk group A, 21 in group B, and 11 in group C. ### results Median time to relapse after diagnosis was 4.5 months (range 2.4-13.6). Thirty-two patients received salvage therapy. <b style='color:DodgerBlue;'><i>Twenty-seven</i></b> <b style='color:DodgerBlue;'><i>received</i></b> <b style='color:MediumOrchid;'><i>rituximab</i></b> <b style='color:DodgerBlue;'><i>mainly</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>addition</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>high-dose</i></b> <b style='color:MediumOrchid;'><i>cytarabine</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>etoposide</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>n</i></b> <b style='color:DodgerBlue;'><i>=</i></b> <b style='color:DodgerBlue;'><i>18</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and/or</i></b> <b style='color:MediumOrchid;'><i>ifosfamide</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>carboplatin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>etoposide</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>n</i></b> <b style='color:DodgerBlue;'><i>=</i></b> <b style='color:DodgerBlue;'><i>7</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b> First-line salvage chemotherapy response rate was 66% with 47% being complete remission (CR). Twenty-one patients received high-dose chemotherapy (HDC) followed by autologous (n = 13) or allogeneic (n = 8) transplant. With a median follow-up of 6.8 years, the 5-year survival rate after relapse was 36.4% (95% confidence interval [CI] 22-53%). Twelve patients were still alive; all but one (group A) received consolidation treatment. Achieving CR before consolidation was significantly associated with better survival, with a 5-year survival rate of 75% (95% CI 46.8-91.1%) for patients in CR before HDC, 33% (95% CI 9.7-70%) for patients in partial remission, and 0% for nonresponders (P = .033). ### conclusion Survival of children/adolescents with mature B-cell lymphoma/leukemia remains poor after relapse with no apparent improvement with <b style='color:Tomato;'><i>rituximab</i></b>. Response rates to salvage chemo-immunotherapies are insufficient and new drugs are urgently needed to improve disease control.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi_:</b>  In metastastic patients , the combination of  <span class="marker" data-anno-id="0" data-anno-label="P1">gemcitabine</span>  and  <span class="marker" data-anno-id="1" data-anno-label="P1">cisplatin</span>  has become the new standard regimen due to a lower toxicity in comparison to the combination of  <span class="marker" data-anno-id="2" data-anno-label="C1">methotrexate</span>  ,  <span class="marker" data-anno-id="3" data-anno-label="C1">vinblastine</span>  ,  <span class="marker" data-anno-id="4" data-anno-label="C1">doxorubicin</span>  , and cisplatin ( MVAC ) . </div></div><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yakir:</b>  In metastastic patients , the combination of  <span class="marker" data-anno-id="0" data-anno-label="P1">gemcitabine</span>  and  <span class="marker" data-anno-id="1" data-anno-label="P1">cisplatin</span>  has become the new standard regimen due to a lower toxicity in comparison to the combination of  <span class="marker" data-anno-id="2" data-anno-label="N1">methotrexate</span>  ,  <span class="marker" data-anno-id="3" data-anno-label="N1">vinblastine</span>  ,  <span class="marker" data-anno-id="4" data-anno-label="N1">doxorubicin</span>  , and  <span class="marker" data-anno-id="5" data-anno-label="N1">cisplatin</span>  ( MVAC ) . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>[Neoadjuvant or Adjuvant Chemotherapy for Bladder Cancer?].</u></h4>Advanced urothelial carcinoma of the bladder is associated with a high metastatic potential. Life expectancy for metastatic patients is poor and rarely exceeds more than one year without further therapy. Neoadjuvant chemotherapy can decrease the tumour burden while reducing the risk of death. Adjuvant chemotherapy has been discussed controversially. Patients with lymph node-positive metastases seem to benefit the most from adjuvant chemotherapy. In selected patients, metastasectomy can prolong survival. <b style='color:DodgerBlue;'><i>In</i></b> <b style='color:DodgerBlue;'><i>metastastic</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>gemcitabine</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>cisplatin</i></b> <b style='color:DodgerBlue;'><i>has</i></b> <b style='color:DodgerBlue;'><i>become</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>new</i></b> <b style='color:DodgerBlue;'><i>standard</i></b> <b style='color:DodgerBlue;'><i>regimen</i></b> <b style='color:DodgerBlue;'><i>due</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>lower</i></b> <b style='color:DodgerBlue;'><i>toxicity</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>comparison</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>methotrexate</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>vinblastine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>doxorubicin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>cisplatin</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>MVAC</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b> For second-line treatment, vinflunine is the only approved therapeutic agent.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi_:</b>  Interestingly ,  <span class="marker" data-anno-id="0" data-anno-label="P1">aspirin</span>  not only significantly inhibited the growth of TNBC cells , but also attenuated YAP and β-catenin expression by upregulating the E3 ubiquitin ligase β-TrCP to abolished  <span class="marker" data-anno-id="1" data-anno-label="P1">docetaxel</span>  and  <span class="marker" data-anno-id="2" data-anno-label="P1">vinorelbine</span>  resistance . </div></div><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yakir:</b>  Interestingly ,  <span class="marker" data-anno-id="0" data-anno-label="C2">aspirin</span>  not only significantly inhibited the growth of TNBC cells , but also attenuated YAP and β-catenin expression by upregulating the E3 ubiquitin ligase β-TrCP to abolished  <span class="marker" data-anno-id="1" data-anno-label="C2">docetaxel</span>  and  <span class="marker" data-anno-id="2" data-anno-label="C2">vinorelbine</span>  resistance . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Aspirin attenuates YAP and β-catenin expression by promoting β-TrCP to overcome docetaxel and vinorelbine resistance in triple-negative breast cancer.</u></h4>The use of <b style='color:Tomato;'><i>aspirin</i></b> has been associated with reduced breast cancer risk, but it is litter known if <b style='color:Tomato;'><i>aspirin</i></b> overcomes chemoresistance in triple-negative breast cancer (TNBC). Herein, we demonstrated that changes in the expression of Yes-associated protein (YAP) and β-catenin might be a promising predictive biomarker for neoadjuvant chemotherapy sensitivity in TNBC patients. Inhibition of YAP or β-catenin enhanced the cytotoxicity of the anti-microtubule agents <b style='color:Tomato;'><i>docetaxel</i></b> and <b style='color:Tomato;'><i>vinorelbine</i></b> against drug-resistant TNBC cells as well as the sensitivity of these cells to the agents in vitro and in vivo. <b style='color:DodgerBlue;'><i>Interestingly</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>aspirin</i></b> <b style='color:DodgerBlue;'><i>not</i></b> <b style='color:DodgerBlue;'><i>only</i></b> <b style='color:DodgerBlue;'><i>significantly</i></b> <b style='color:DodgerBlue;'><i>inhibited</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>growth</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>TNBC</i></b> <b style='color:DodgerBlue;'><i>cells</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>but</i></b> <b style='color:DodgerBlue;'><i>also</i></b> <b style='color:DodgerBlue;'><i>attenuated</i></b> <b style='color:DodgerBlue;'><i>YAP</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>β-catenin</i></b> <b style='color:DodgerBlue;'><i>expression</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>upregulating</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>E3</i></b> <b style='color:DodgerBlue;'><i>ubiquitin</i></b> <b style='color:DodgerBlue;'><i>ligase</i></b> <b style='color:DodgerBlue;'><i>β-TrCP</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>abolished</i></b> <b style='color:MediumOrchid;'><i>docetaxel</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>vinorelbine</i></b> <b style='color:DodgerBlue;'><i>resistance</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The combination of <b style='color:Tomato;'><i>aspirin</i></b> and <b style='color:Tomato;'><i>docetaxel</i></b> or <b style='color:Tomato;'><i>vinorelbine</i></b> remarkably inhibited the growth of drug-resistant TNBC cells in vitro and in vivo. Moreover, TNBC patients with high YAP and/or β-catenin expression had a higher risk of relapse or mortality than patients with low YAP and/or β-catenin expression. Collectively, our study discovered a novel role of <b style='color:Tomato;'><i>aspirin</i></b> based on its anticancer effect, and put forward some possible mechanisms of chemoresistance in TNBC. The combined use of <b style='color:Tomato;'><i>aspirin</i></b> and anti-microtubule drugs presented several promising therapeutic approaches for TNBC treatment.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi_:</b>  Mycophenolate mofetil resulted in rapid improvement of steroid-refractory immune-related adverse event hepatitis , induced by  <span class="marker" data-anno-id="0" data-anno-label="C1">nivolumab</span>  plus  <span class="marker" data-anno-id="1" data-anno-label="C1">ipilimumab</span>  . </div></div><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yakir:</b>  Mycophenolate mofetil resulted in rapid improvement of steroid-refractory immune-related adverse event hepatitis , induced by  <span class="marker" data-anno-id="0" data-anno-label="N1">nivolumab</span>  plus  <span class="marker" data-anno-id="1" data-anno-label="N1">ipilimumab</span>  . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Successful mycophenolate mofetil treatment of a patient with severe steroid-refractory hepatitis evoked by nivolumab plus ipilimumab treatment for relapsed bladder cancer.</u></h4> <b style='color:MediumOrchid;'><i>Mycophenolate</i></b> <b style='color:DodgerBlue;'><i>mofetil</i></b> <b style='color:DodgerBlue;'><i>resulted</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>rapid</i></b> <b style='color:DodgerBlue;'><i>improvement</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>steroid-refractory</i></b> <b style='color:DodgerBlue;'><i>immune-related</i></b> <b style='color:DodgerBlue;'><i>adverse</i></b> <b style='color:DodgerBlue;'><i>event</i></b> <b style='color:DodgerBlue;'><i>hepatitis</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>induced</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:MediumOrchid;'><i>nivolumab</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>ipilimumab</i></b> <b style='color:DodgerBlue;'><i>.</i></b></div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi_:</b>  This study was performed to compare the efficacy of peritonsillar infiltration of bupivacaine , tramadol and combination of bupivacaine-tramadol in post-tonsillectomy pain . </div></div><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yakir:</b>  This study was performed to compare the efficacy of peritonsillar infiltration of  <span class="marker" data-anno-id="0" data-anno-label="P1">bupivacaine</span>  ,  <span class="marker" data-anno-id="1" data-anno-label="P1">tramadol</span>  and combination of bupivacaine-tramadol in post-tonsillectomy pain . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Preemptive peritonsillar infiltration with bupivacaine in combination with tramadol improves pediatric post-tonsillectomy pain better than using bupivacaine or tramadol alone: A randomized, placebo-controlled, double blind clinical trial.</u></h4>Post-tonsillectomy pain is one of the most common problems after anesthesia, therefore use of a good anesthesia technique with minimum side effect is an important aim. <b style='color:DodgerBlue;'><i>This</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>performed</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>compare</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>efficacy</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>peritonsillar</i></b> <b style='color:DodgerBlue;'><i>infiltration</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>bupivacaine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>tramadol</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>bupivacaine-tramadol</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>post-tonsillectomy</i></b> <b style='color:DodgerBlue;'><i>pain</i></b> <b style='color:DodgerBlue;'><i>.</i></b> ### Materials And Methods In a double blind trial 120 ASA I and II children condidated for tonsillectomy were randomized into four groups: Peritonsillar infiltration with <b style='color:Tomato;'><i>bupivacaine</i></b> 1 mg/kg in Group B, <b style='color:Tomato;'><i>tramadol</i></b> 2 mg/kg in Group T, combination of <b style='color:Tomato;'><i>bupivacaine</i></b>-<b style='color:Tomato;'><i>tramadol</i></b> in Group BT and saline in Group C was done. ### results Until 60 minutes in the recovery room, control of pain in the first three groups were better than Group C (P < 0.05) and in the third group it was better than others. Four hours after surgery, control of pain was better in the second and third groups in comparison to Groups B and Group C (P <0.05) and was better in the third group in comparison to the second group. Then, 24 hours after that, only in the group III the control of pain was effective (P < 0.05). ### conclusions In this study we showed that peritonsillar infiltration with combination of bupivacain-<b style='color:Tomato;'><i>tramadol</i></b> provided less post surgery pain compared with infiltration of <b style='color:Tomato;'><i>bupivacaine</i></b> and <b style='color:Tomato;'><i>tramadol</i></b> alone in adenotonsillectomy of children.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi_:</b>  A significant reduction in plasma 8-isoprostane and oxLDL levels was observed in all treatment groups [ by 10 % , 8 % and 6 % ( p < 0.05 compared with baseline ) and 41 % , 40 % and 39 % ( p < 0.001 compared with baseline ) in simvastatin , simvastatin/ezetimibe and rosuvastatin groups , respectively ] . </div></div><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yakir:</b>  A significant reduction in plasma 8-isoprostane and oxLDL levels was observed in all treatment groups [ by 10 % , 8 % and 6 % ( p < 0.05 compared with baseline ) and 41 % , 40 % and 39 % ( p < 0.001 compared with baseline ) in  <span class="marker" data-anno-id="0" data-anno-label="P1">simvastatin</span>  ,  <span class="marker" data-anno-id="1" data-anno-label="P1">simvastatin/ezetimibe</span>  and rosuvastatin groups , respectively ] . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Comparison of the effect of simvastatin versus simvastatin/ezetimibe versus rosuvastatin on markers of inflammation and oxidative stress in subjects with hypercholesterolemia.</u></h4>Statins may exhibit anti-inflammatory and antioxidant effects. Whether different statins at equivalent doses or the combination of low-dose statin with <b style='color:Tomato;'><i>ezetimibe</i></b> have comparable anti-inflammatory and antioxidant effects is unknown. The aim of this study was to compare the effects of <b style='color:Tomato;'><i>simvastatin</i></b>, <b style='color:Tomato;'><i>simvastatin</i></b>/<b style='color:Tomato;'><i>ezetimibe</i></b> or <b style='color:Tomato;'><i>rosuvastatin</i></b> at equivalent low-density lipoprotein cholesterol lowering doses on inflammation and oxidative stress indices in subjects with hypercholesterolemia. ### methods This was a pre-specified analysis of a prospective, randomized, open-label, blinded endpoint (PROBE) study. We enrolled one hundred and fifty three (n = 153) hypercholesterolemic subjects who were randomized to receive <b style='color:Tomato;'><i>simvastatin</i></b> 40 mg or <b style='color:Tomato;'><i>simvastatin</i></b>/<b style='color:Tomato;'><i>ezetimibe</i></b> 10/10 mg or <b style='color:Tomato;'><i>rosuvastatin</i></b> 10 mg daily. Plasma 8-Epi prostaglandin F2 alpha (8-epiPGF2a), oxidized LDL (oxLDL) and lipoprotein-associated phospholipase A2 (Lp-PLA2) activity and mass were measured at baseline and following 12 weeks of treatment. ### results <b style='color:DodgerBlue;'><i>A</i></b> <b style='color:DodgerBlue;'><i>significant</i></b> <b style='color:DodgerBlue;'><i>reduction</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>plasma</i></b> <b style='color:DodgerBlue;'><i>8-isoprostane</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>oxLDL</i></b> <b style='color:DodgerBlue;'><i>levels</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>observed</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>all</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>groups</i></b> <b style='color:DodgerBlue;'><i>[</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>10</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>8</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>6</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>p</i></b> <b style='color:DodgerBlue;'><i><</i></b> <b style='color:DodgerBlue;'><i>0.05</i></b> <b style='color:DodgerBlue;'><i>compared</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>baseline</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>41</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>40</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>39</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>p</i></b> <b style='color:DodgerBlue;'><i><</i></b> <b style='color:DodgerBlue;'><i>0.001</i></b> <b style='color:DodgerBlue;'><i>compared</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>baseline</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:MediumOrchid;'><i>simvastatin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>simvastatin/ezetimibe</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>rosuvastatin</i></b> <b style='color:DodgerBlue;'><i>groups</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>respectively</i></b> <b style='color:DodgerBlue;'><i>]</i></b> <b style='color:DodgerBlue;'><i>.</i></b> In all treatment groups a significant reduction in total plasma Lp-PLA2 activity and mass was observed (by 36%, 31% and 38% and 36%, 32% and 32% for <b style='color:Tomato;'><i>simvastatin</i></b>, <b style='color:Tomato;'><i>simvastatin</i></b>/<b style='color:Tomato;'><i>ezetimibe</i></b> and <b style='color:Tomato;'><i>rosuvastatin</i></b>, respectively, p < 0.001 compared with baseline). No intergroup differences were observed. ### conclusions <b style='color:Tomato;'><i>simvastatin</i></b> 40 mg, <b style='color:Tomato;'><i>simvastatin</i></b>/<b style='color:Tomato;'><i>ezetimibe</i></b> 10/10 mg and <b style='color:Tomato;'><i>rosuvastatin</i></b> 10 mg significantly reduced 8-epiPGF2a, oxLDL and Lp-PLA2 activity and mass to a similar extent.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi_:</b>  Blood was sampled immediately prior to premedication (  <span class="marker" data-anno-id="0" data-anno-label="C1">temazepam</span>  ) , after induction of anaesthesia (  <span class="marker" data-anno-id="1" data-anno-label="C1">fentanyl</span>  and  <span class="marker" data-anno-id="2" data-anno-label="C1">thiopentone</span>  ) and at 10-minute intervals until the end of the procedure ( N2O maintenance ,  <span class="marker" data-anno-id="3" data-anno-label="C1">vecuronium</span>  relaxation ) . </div></div><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yakir:</b>  Blood was sampled immediately prior to premedication (  <span class="marker" data-anno-id="0" data-anno-label="C2">temazepam</span>  ) , after induction of anaesthesia (  <span class="marker" data-anno-id="1" data-anno-label="C2">fentanyl</span>  and  <span class="marker" data-anno-id="2" data-anno-label="C2">thiopentone</span>  ) and at 10-minute intervals until the end of the procedure ( N2O maintenance , vecuronium relaxation ) . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>The plasma ACTH, AVP, CRH and catecholamine responses to conventional and laparoscopic cholecystectomy.</u></h4>We compared the responses of the stress hormones, cortisol, ACTH, <b style='color:Tomato;'><i>vasopressin</i></b> (AVP), corticotrophin releasing hormone (CRH) and catecholamines to elective conventional and laparoscopic cholecystectomy. ### design A right upper quadrant transverse incision was used for conventional cholecystectomy, and four 1-2-cm incisions for the laparoscopic procedure (for insertion of surgical instruments, diathermy, fibreoptic telescope and light source, and carbon dioxide insufflation). <b style='color:DodgerBlue;'><i>Blood</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>sampled</i></b> <b style='color:DodgerBlue;'><i>immediately</i></b> <b style='color:DodgerBlue;'><i>prior</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>premedication</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:MediumOrchid;'><i>temazepam</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>after</i></b> <b style='color:DodgerBlue;'><i>induction</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>anaesthesia</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>fentanyl</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>thiopentone</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>at</i></b> <b style='color:DodgerBlue;'><i>10-minute</i></b> <b style='color:DodgerBlue;'><i>intervals</i></b> <b style='color:DodgerBlue;'><i>until</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>end</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>procedure</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>N2O</i></b> <b style='color:DodgerBlue;'><i>maintenance</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>vecuronium</i></b> <b style='color:DodgerBlue;'><i>relaxation</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b> A blood sample was taken after reversal, and then at 10-minute intervals for 50 minutes. Plasma sodium and blood pressure were measured at similar intervals. Results are expressed as mean +/- standard error. ### patients Twelve patients were studied (six in each group). ### measurements Peptide hormones were measured by radioimmunoassay, cortisol by ELISA and catecholamines by HPLC. ### results The mean premedication hormone values for the conventional and laparoscopic procedures did not increase significantly after induction of anaesthesia. Within 10 minutes of the first incision, however, there was a marked concordant rise in mean plasma ACTH and AVP levels for both procedures (conventional: ACTH, from a premedication value of 10.2 +/- 1.7 to 80.1 +/- 14.3 pmol/l, AVP from 1.2 +/- 0.4 to 117 +/- 24 pmol/l, P < 0.01 for both hormones; laparoscopic: ACTH from 5.8 +/- 2.6 to 55.1 +/- 26.0 pmol/l, AVP from 1.6 +/- 0.11 to 49.2 +/- 27.09 pmol/l). At the end of both types of operation mean levels of ACTH and AVP were still elevated, although the ACTH: AVP ratio had increased. Greater variability in ACTH and AVP responses was seen in the laparoscopic than in the conventional procedure, three patients showing a relatively small response to surgery. Total secretion of ACTH during both types of surgery was not significantly less both during (P < 0.05), and after (P < 0.01) laparoscopic surgery. For both procedures, the timing of AVP and ACTH peaks was significantly related (P < 0.002). A small but significant rise in CRH was observed 30 minutes after the start of surgery for both procedures P < 0.05). The timing of CRH and ACTH peaks was unrelated. The maximum mean plasma cortisol level for the conventional procedure (1268 +/- 147 nmol/l) was reached 20 minutes after reversal of anaesthesia and remained at this level until the end of sampling. The cortisol response was comparable during the laparoscopic procedure but was beginning to fall at 60 minutes post-operatively. Plasma adrenaline responses to the two types of surgery were not significantly different, but the plasma total noradrenaline response to laparoscopic surgery as indicated by the response area during the first 20 minutes was significantly increased (P < 0.02). Plasma sodium, renin activity and initial systolic blood pressure fall were not significantly different during the two procedures. ### conclusions For both procedures, the peak of ACTH secretion after incision is likely to be AVP dependent, and the timing of peak levels of these two hormones was significantly related. Subsequent ACTH secretion may be the result of an interaction between AVP and CRH. Laparoscopic cholecystectomy results in a smaller AVP rise than does the conventional procedure, and plasma AVP falls more rapidly post-operatively. During the period of observation, ACTH, CRH, cortisol and adrenaline responses were not significantly lessened by the laparoscopic approach, but there was a significant increase in the noradrenaline response. Stress hormone monitoring may assist further improvements in surgical technique.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi_:</b>  The study objectives were to evaluate the safety , tolerability , and preliminary efficacy of multiple doses of  <span class="marker" data-anno-id="0" data-anno-label="P1">dulanermin</span>  in combination with modified  <span class="marker" data-anno-id="1" data-anno-label="P1">FOLFOX6</span>  and  <span class="marker" data-anno-id="2" data-anno-label="P1">bevacizumab</span>  in previously untreated patients with locally advanced , recurrent , or metastatic colorectal cancer . </div></div><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yakir:</b>  The study objectives were to evaluate the safety , tolerability , and preliminary efficacy of multiple doses of  <span class="marker" data-anno-id="0" data-anno-label="C1">dulanermin</span>  in combination with modified  <span class="marker" data-anno-id="1" data-anno-label="C1">FOLFOX6</span>  and  <span class="marker" data-anno-id="2" data-anno-label="C1">bevacizumab</span>  in previously untreated patients with locally advanced , recurrent , or metastatic colorectal cancer . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>A phase 1B study of dulanermin in combination with modified FOLFOX6 plus bevacizumab in patients with metastatic colorectal cancer.</u></h4> <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>objectives</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>evaluate</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>safety</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>tolerability</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>preliminary</i></b> <b style='color:DodgerBlue;'><i>efficacy</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>multiple</i></b> <b style='color:DodgerBlue;'><i>doses</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>dulanermin</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>modified</i></b> <b style='color:DodgerBlue;'><i>FOLFOX6</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>bevacizumab</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>previously</i></b> <b style='color:DodgerBlue;'><i>untreated</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>locally</i></b> <b style='color:DodgerBlue;'><i>advanced</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>recurrent</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>metastatic</i></b> <b style='color:DodgerBlue;'><i>colorectal</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>.</i></b> ### Patients And Methods A total of 23 patients received <b style='color:Tomato;'><i>dulanermin</i></b> at dosages of 4.5 or 9 mg/kg/d given on days 1 to 3 of each 14-day cycle along with standard dosing of modified FOLFOX6 plus <b style='color:Tomato;'><i>bevacizumab</i></b>. Dose-limiting toxicities, adverse events (AEs), maximum tolerated dose, and response according to Response Evaluation Criteria in Solid Tumors were assessed. ### results In the first cohort (3 patients given <b style='color:Tomato;'><i>dulanermin</i></b> at 4.5 mg/kg/d) and second cohort (6 patients given <b style='color:Tomato;'><i>dulanermin</i></b> at 9 mg/kg/day), no dose-limiting toxicities were observed. The subsequent 14 patients were treated with a <b style='color:Tomato;'><i>dulanermin</i></b> dosage of 9 mg/kg/d. Patients (N = 23) received 2 to 42 cycles of <b style='color:Tomato;'><i>dulanermin</i></b> (median 15). The most common grade 3 or 4 AEs were neutropenia (39%), hypertension (17%), peripheral neuropathy (17%), hand-foot syndrome (13%), and pulmonary embolism (13%). Three patients (13%) discontinued the study because of serious AEs. Overall, a best response of partial response was observed in 13 patients (57%) (9 confirmed, 4 unconfirmed), stable disease was observed in 7 patients (30%), and disease progression was observed in 3 patients (13%). The median progression-free survival was 9.9 months (95% confidence interval, 7.0-12.7). ### conclusions Overall, the addition of <b style='color:Tomato;'><i>dulanermin</i></b> to first-line FOLFOX plus <b style='color:Tomato;'><i>bevacizumab</i></b> was well tolerated in patients with advanced colorectal cancer, with similar AEs that would be expected from FOLFOX plus <b style='color:Tomato;'><i>bevacizumab</i></b>. A randomized study is required to assess the clinical efficacy of <b style='color:Tomato;'><i>dulanermin</i></b> in this patient population.</div></div></div><div class="supercontainer"><div class="midcontainer"><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yosi_:</b>  Rats were distributed into three groups ( n = 5 ) according to the drug studied namely , 50 % enantiomeric excess bupivacaine mixture ( 5 μg/mL ) ; pancuronium ( 2 μg/mL ) ; 50 % enantiomeric excess  <span class="marker" data-anno-id="0" data-anno-label="C1">bupivacaine</span>  mixture +  <span class="marker" data-anno-id="1" data-anno-label="C1">pancuronium</span>  . </div></div><div class="container"><div class="annotation-head"></div><div class="annotation-segment"><b>Yakir:</b>  Rats were distributed into three groups ( n = 5 ) according to the drug studied namely , 50 % enantiomeric excess bupivacaine mixture ( 5 μg/mL ) ;  <span class="marker" data-anno-id="0" data-anno-label="P1">pancuronium</span>  ( 2 μg/mL ) ; 50 % enantiomeric excess  <span class="marker" data-anno-id="1" data-anno-label="P1">bupivacaine</span>  mixture + pancuronium . </div></div></div><div class="abstractcontainer"><button type="button" class="collapsible" style="background-color:#eee">Click to see abstract</button><div style="display:none"><h4><u>Effect of 50% enantiomeric excess bupivacaine mixture combined with pancuronium on neuromuscular transmission in rat phrenic nerve-diaphragm preparation; a pilot study.</u></h4>Local anaesthetics are drugs that are widely used in clinical practice. However, the effects of these drugs on the neuromuscular junction and their influence on the blockade produced by non-depolarising neuromuscular blocking drugs are still under investigation. The aim of this study was to evaluate, in vitro, the influence of a 50% enantiomeric excess <b style='color:Tomato;'><i>bupivacaine</i></b> mixture on neuromuscular transmission and neuromuscular block produced by <b style='color:Tomato;'><i>pancuronium</i></b>. ### methods <b style='color:DodgerBlue;'><i>Rats</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>distributed</i></b> <b style='color:DodgerBlue;'><i>into</i></b> <b style='color:DodgerBlue;'><i>three</i></b> <b style='color:DodgerBlue;'><i>groups</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>n</i></b> <b style='color:DodgerBlue;'><i>=</i></b> <b style='color:DodgerBlue;'><i>5</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>according</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>drug</i></b> <b style='color:DodgerBlue;'><i>studied</i></b> <b style='color:DodgerBlue;'><i>namely</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>50</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>enantiomeric</i></b> <b style='color:DodgerBlue;'><i>excess</i></b> <b style='color:MediumOrchid;'><i>bupivacaine</i></b> <b style='color:DodgerBlue;'><i>mixture</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>5</i></b> <b style='color:DodgerBlue;'><i>μg/mL</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>;</i></b> <b style='color:MediumOrchid;'><i>pancuronium</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>2</i></b> <b style='color:DodgerBlue;'><i>μg/mL</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>;</i></b> <b style='color:DodgerBlue;'><i>50</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>enantiomeric</i></b> <b style='color:DodgerBlue;'><i>excess</i></b> <b style='color:MediumOrchid;'><i>bupivacaine</i></b> <b style='color:DodgerBlue;'><i>mixture</i></b> <b style='color:DodgerBlue;'><i>+</i></b> <b style='color:MediumOrchid;'><i>pancuronium</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The following parameters were evaluated: (1) Effects of a 50% enantiomeric excess <b style='color:Tomato;'><i>bupivacaine</i></b> mixture on membrane potential (MP) and miniature endplate potentials (MEPPs); (2) amplitude of diaphragmatic response before and 60 min after the addition of a 50% enantiomeric excess <b style='color:Tomato;'><i>bupivacaine</i></b> mixture; the degree of neuromuscular block with <b style='color:Tomato;'><i>pancuronium</i></b> and <b style='color:Tomato;'><i>pancuronium</i></b> combined with a 50% enantiomeric excess <b style='color:Tomato;'><i>bupivacaine</i></b> mixture. ### results A 50% enantiomeric excess <b style='color:Tomato;'><i>bupivacaine</i></b> mixture did not alter the amplitude of muscle response (MP) but decreased the frequency and amplitude of MEPP. The block produced by <b style='color:Tomato;'><i>pancuronium</i></b> was potentiated by a 50% enantiomeric excess <b style='color:Tomato;'><i>bupivacaine</i></b> mixture. ### conclusion A 50% enantiomeric excess <b style='color:Tomato;'><i>bupivacaine</i></b> mixture used alone did not affect neuromuscular transmission, but potentiated the neuromuscular block produced by <b style='color:Tomato;'><i>pancuronium</i></b>. No action was shown on the muscle fibre, and alterations on MEPPs demonstrated a presynaptic action.</div></div></div></div>

<script>
    var coll = document.getElementsByClassName("collapsible");
    var i;

    for (i = 0; i < coll.length; i++) {
        coll[i].addEventListener("click", function () {
            var content = this.nextElementSibling;
            console.log(content.style)
            if (content.style.display === "block") {
                content.style.display = "none";
            } else {
                content.style.display = "block";
            }
        });
    }
</script>
</body>

</html>